BPGbio, Inc.

BPGbio is a biology-first, AI-powered clinical-stage biopharmaceutical company focused on mitochondrial biology and protein homeostasis. Its pipeline includes AI-developed therapeutics for oncology, rare diseases and neurology, including candidates in late-stage clinical trials. The company’s proprietary NAi Interrogative Biology platform uses patient biology and AI-driven analysis to model disease and accelerate drug discovery and development, aiming to improve how diseases are understood, diagnosed and treated.